Cullgen is developing innovative targeted protein degradation (TPD) therapeutics. Their proprietary technology platform, uSMITE™, leverages the power of E3 ligases to allow them to create small molecules that selectively degrade disease-causing proteins. Cullgen's pipeline includes several promising drug candidates targeting various therapeutic areas, including oncology, inflammation, and neurodegeneration. Their research has the potential to revolutionize the treatment of these diseases by addressing previously undruggable targets.

Cullgen

Astellas delves deeper into protein degrading drugs with Cullgen deal - BioPharma Dive

Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders - PR Newswire

 Cullgen Announces Additions to Board of Directors and Scientific Advisory Board 

 SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULM 

 Cullgen Closes $50 Million Series B Investment to Advance Targeted Protein Degraders and Novel E3 Ligands Platform 

Cullgen Announces Additions to Board of Directors and Scientific Advisory Board - Business Wire

 Modified proteins and protein degraders 

Astellas, Cullgen Partner to Advance Targeted Protein Degraders - Contract Pharma

 PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM 

Below, a brief spotlight on Cullgen's Seth Goldblum, SVP - Corporate Development. Seth will be at the 24th Annual Biotech in Europe Forum this September, message us if you'd like to organize a meeting!

Cullgen Entering Public Market with Pulmatrix Merger - San Diego Business Journal

Astellas Bets Potential $1.9B on Cullgen’s Protein Degrader Tech - BioSpace

Cullgen Announces First-In-Human Dose in Phase I/II Trial of CG001419, a First-in-Class TRK Protein Degrader for Treatment of Cancer Patients - Business Wire

Degrader-Antibody Conjugates, or DACs, are an emerging class of drug therapies poised to revolutionize cancer treatments... but what are they exactly?

Check out our new DAC webpage to learn all about them! Visit www.cullgen.com/dacs

May 12 Quick Takes: AZ latest pharma to gain rights to a LaNova ADC - BioCentury

Cullgen members will be attending the following conferences in Europe this month:

- 14th World ADC in London, UK (3/12-15) https://lnkd.in/eVkYdzm
- BIO-Europe Spring in Barcelona, Spain (3/18-20) https://lnkd.in/eRdjEqv
- Keystone Symposia on Immunometabolism in Killarney, Ireland (3/18-21) https://lnkd.in/g-wbfEue

Please message us if you'd like to organize a meeting!

Astellas and Cullgen to develop small molecule protein degraders - Pharmaceutical Technology

Cullgen Inc., is a San Diego based biotechnology company developing small molecule therapeutics based on our proprietary targeted protein degradation (TPD) technology, uSMITE™. Our TPD technology is a type of precision medicine that has the potential to address a broad range of intracellular disease targets, such as oncology, inflammation, pain, and other diseases that cannot be addressed by existing therapies, commonly referred to as “undruggable” targets. We are currently developing a number of TPD based therapeutics in-house, primarily for oncology, that are available for co-development or licensure. Our most advanced candidate, CG001419, is now in a phase I/II clinical trial for cancer and we are preparing to start a phase I clinical trial for this product in pain applications.

In addition to our internal pipeline of TPD programs, we are also discovering and developing novel E3 ligands in order to enhance the overall robustness and effectiveness of TPD therapeutics. We believe that the development of novel E3 ligands will be one of the key long-term success factors for this technology. Through the use of novel E3 ligands, we will be able to design TPDs that are capable of recruiting and binding to one of the hundreds of existing E3 ligases that have never been utilized as part of TPD therapeutic. Designing a TPD that has the capability to bind to different E3 ligases will likely provide a therapeutic solution with reduced toxicity, enhanced tissue selectivity and overcome existing drug resistance.

Cullgen is also actively developing degrader - antibody conjugates (DACs) based on the conjugation of some of our highly potent degraders with monoclonal antibodies (MAbs). The use of a degrader as a payload will provide additional drug specificity to increase overall efficacy and safety.

Meet Cullgen Inc. @ #Sachs_BEF

More Info @ https://lnkd.in/d7zEuKym

#BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

Cullgen Closes $50 Million Series B Investment to Advance Targeted Protein Degraders and Novel E3 Ligands Platform - Business Wire

Cullgen patents new DCAF1-binding PROTACs for cancer - BioWorld Online

 Cullgen patents new DCAF1-binding PROTACs for cancer 

Astellas and Cullgen announce protein degrader partnership worth up to $1.9bn - PMLiVE

Cullgen's Satya (Nanu) Das, MD, MSCI, will be leading a roundtable discussion at Immuno-Oncology Xchange in September! Details below.

 Astellas Bets Potential $1.9B on Cullgen’s Protein Degrader Tech 

Cullgen Raises $40 Million in New Financing Led by AstraZeneca-CICC Fund - Business Wire

 Compounds and methods of treating cancers 

Pulmatrix and Cullgen Announce Proposed Merger - PR Newswire

A dive into how Cullgen uses novel E3 ligands to "drug the undruggable."

For more information, visit https://lnkd.in/gRerc5CC 

Astellas adds Cullgen to parade of protein degrader pacts, ...

 Cullgen Entering Public Market with Pulmatrix Merger 

Pulmatrix Shares Surge on Merger with Cullgen - MarketWatch

Shareholder Alert: Ademi LLP investigates whether Pulmatrix, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire

Astellas notches another protein degrader pact with $21M upfront for PeptiDream - Fierce Biotech

 Protein Engineering Market Projected to Reach USD 7.39 Billion by 2032 with a CAGR of 14.72% - SNS Insider 

Cullgen and Pulmatrix set for merger, eye clinical trials - Investing.com

 Cullgen Raises $40 Million in New Financing Led by AstraZ... 

How do targeted protein degraders work to fight diseases? Watch this video for a brief overview.

For more information, visit https://lnkd.in/eNEPz9Wj

 Sector Update: Health Care Stocks Edge Lower Wednesday Afternoon 

Pulmatrix and Cullgen Announce Strategic Merger Agreement - TipRanks

 Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders 

 Tropomyosin receptor kinase (trk) degradation compounds and methods of use 

Pulmatrix and Cullgen to Merge - citybiz

Pulmatrix to Merge with Cullgen - Contract Pharma

Cullgen to Absorb Pulmatrix, Join Nasdaq - MarketWatch

A successful panel at Basel! Seth Goldblum, Senior VP of Corporate Development, joined a panel with other biotechnology experts discussing the intricacies of partnering in oncology. He provided an overview of Cullgen and available collaboration opportunities - message us if you have any questions!

Astellas adds Cullgen to parade of protein degrader pacts, paying $35M upfront to access tech - Fierce Biotech

Don't miss the LES Deals of Distinction Award Winner Presentation this Thursday, March 7! Cullgen's Seth Goldblum and Astellas' Tomohiro Yamauchi will be discussing the nature of the strategic collaboration between the two companies. 

The presentation will take place virtually from 4-5pm PST. More details and registration here: https://lnkd.in/g-w6_xck

 Shareholder Alert: Ademi LLP investigates whether Pulmatrix, Inc. is obtaining a Fair Price for its Public Shareholders 

Cullgen

Business:

Drug notes:

About: